Therapeutic Action
Combination of two antibacterials: a sulfonamide (sulfamethoxazole) and a diaminopyrimidine antifolate (trimethoprim)
Source page 103
Loading InternPractice…
Individual generic drug information
Extracted information for CO-TRIMOXAZOLE only.
Combination of two antibacterials: a sulfonamide (sulfamethoxazole) and a diaminopyrimidine antifolate (trimethoprim)
Source page 103
Treatment of cerebral toxoplasmosis, pneumocystosis, isosporiasis, cyclosporiasis and brucellosis Prophylaxis of pneumocystosis, toxoplasmosis and isosporiasis Second-line treatment of pertussis Uncomplicated typhoid fever if the strain is susceptible (recent drug susceptibility test)
Source page 103
Extracted information for CO-TRIMOXAZOLE only.
Do not administer: to children under 6 weeks (risk of neonatal hyperbilirubinemia and haemolysis), except for the treatment and prophylaxis of pneumocystosis; to patients with severe renal or hepatic impairment or with history of hypersensitivity to sulfonamides. May cause: haemolytic anaemia in patients with G6PD deficiency, haematologic disorders (thrombocytopenia, leucopenia, agranulocytosis, megaloblastic anaemia due to folic acid deficiency); hypersensitivity reactions (including severe cutaneous reactions such as Stevens-Johnson, Lyell and DRESS syndromes). Early symptoms such as fever, rash, mouth ulcers and bleeding require immediate medical attention. In all these cases, stop treatment immediately. gastrointestinal disturbances, hepatic or renal disorders (crystalluria, etc.), metabolic disorders (hyperkalaemia, hypoglycaemia, hyponatraemia);, neuropathy, photosensitivity (protect skin from sun exposure). In the event of prolonged treatment, monitor full blood count if possible. Avoid or monitor combination with: drugs inducing hyperkalaemia such as potassium salts, spironolactone, enalapril, NSAIDs, heparin (increased risk of hyperkalaemia); phenytoin (increased plasma concentrations of phenytoin); zidovudine (increased risk of haematotoxicity), antidiabetics (increased risk of hypoglycaemia). Drink plenty of water during treatment to reduce risk of crystalluria. Pregnancy: risk of congenital malformations (first trimester) and neonatal haemolysis and hyperbilirubinaemia (after 36 weeks of pregnancy). For prophylaxis and treatment of pneumocystosis in HIV-exposed and HIV-infected women, the benefits outweigh the risks. If used after 36 weeks of pregnancy, observe the child for signs of anaemia or jaundice. For other indications: avoid if possible. Breast-feeding: avoid in women breastfeeding neonates and in women breastfeeding infants that are premature, low birth weight, jaundiced, or ill (same risk as neonates). If used, observe the child for signs of anaemia or jaundice.
Source pages 104, 105
Extracted information for CO-TRIMOXAZOLE only.
400 mg SMX/80 mg TMP and 800 mg SMX/160 mg TMP tablets 100 mg SMX/20 mg TMP dispersible tablet
Source page 103
Treatment of cerebral toxoplasmosis Child 6 weeks and over and adult: 25 mg SMX/5 mg TMP/kg 2 times daily Treatment of pneumocystosis Child 4 weeks and over: 50 mg SMX/10 mg TMP/kg (max. 1600 mg SMX/320 mg TMP) 2 times daily Adult: 1600 mg SMX/320 mg TMP 3 times daily Treatment of isosporiasis and cyclosporiasis Adult: 800 mg SMX/160 mg TMP 2 times daily Prophylaxis of pneumocystosis, toxoplasmosis and isosporiasis Child 4 weeks and over: 50 mg SMX/10 mg TMP/kg (max. 800 mg SMX/160 mg TMP) once daily, as long as necessary Adult: 800 mg SMX/160 mg TMP once daily, as long as necessary Treatment of pertussis, brucellosis and typhoid fever Child 6 weeks and over: 20 mg SMX/4 mg TMP/kg (max. 800 mg SMX/160 mg TMP) 2 times daily Adult: 800 mg SMX/160 mg TMP 2 times daily
Source pages 103, 104
Cyclosporiasis: 7 days Isosporiasis: 7 to 10 days Typhoid fever, pertussis: 14 days Pneumocystosis: 21 days Cerebral toxoplasmosis: 4 to 6 weeks Brucellosis: 6 weeks
Source page 104
Extracted information for CO-TRIMOXAZOLE only.
Preferably take during meals.
Source page 105
– Below 25 °C
Source page 105
Filter the extracted dose blocks for this individual drug.
25 mg SMX/5 mg TMP/kg 2 times daily
Candidate age grouping · source page 103
50 mg SMX/10 mg TMP/kg (max. 1600 mg SMX/320 mg TMP) 2 times daily
Candidate age grouping · source page 103
50 mg SMX/10 mg TMP/kg (max. 800 mg SMX/160 mg TMP) once daily, as long as necessary
Candidate age grouping · source page 103
20 mg SMX/4 mg TMP/kg (max. 800 mg SMX/160 mg TMP) 2 times daily
Candidate age grouping · source page 104